174 related articles for article (PubMed ID: 31945355)
1. Anti-TNF Rechallenge After Infliximab Induced Lupus in Crohn's Disease.
Loebenstein M; Schulberg JD
Gastroenterology; 2020 Jun; 158(8):2069-2071. PubMed ID: 31945355
[No Abstract] [Full Text] [Related]
2. Metabonomics and the Gut Microbiome Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease.
Ding NS; McDonald JAK; Perdones-Montero A; Rees DN; Adegbola SO; Misra R; Hendy P; Penez L; Marchesi JR; Holmes E; Sarafian MH; Hart AL
J Crohns Colitis; 2020 Sep; 14(8):1090-1102. PubMed ID: 32119090
[TBL] [Abstract][Full Text] [Related]
3. Eosinophilic Fasciitis in a Patient With Crohn's Disease Treated With Infliximab. A Rare Coexistence or a Drug-related Manifestation?
Mpitouli A; Kougkas N; Avgoustidis N; Ergazakis N; Karmiris K
Inflamm Bowel Dis; 2020 Jul; 26(8):e77-e78. PubMed ID: 32529216
[No Abstract] [Full Text] [Related]
4. Uncommon Cause of Chest Pain in a 9-Year-Old Boy With Crohn's Disease.
Kollen L; Werner O; Gavotto A
Gastroenterology; 2020 Jun; 158(8):2055-2057. PubMed ID: 32145218
[No Abstract] [Full Text] [Related]
5. Anti-tumor necrosis factor-α induced systemic lupus erythematosus in a patient with metastatic Crohn's disease--what is the role of anti-TNF antibody?
Farkas K; Nagy F; Kovács L; Wittmann T; Molnár T
J Crohns Colitis; 2013 May; 7(4):e143-5. PubMed ID: 22818164
[TBL] [Abstract][Full Text] [Related]
6. TNF-alpha antagonist induced lupus on three different agents.
Mudduluru BM; Shah S; Shamah S; Swaminath A
Postgrad Med; 2017 Mar; 129(2):304-306. PubMed ID: 27748629
[TBL] [Abstract][Full Text] [Related]
7. Extended Analysis Identifies Drug-Specific Association of 2 Distinct HLA Class II Haplotypes for Development of Immunogenicity to Adalimumab and Infliximab.
Powell Doherty RD; Liao H; Satsangi JJ; Ternette N
Gastroenterology; 2020 Aug; 159(2):784-787. PubMed ID: 32275970
[No Abstract] [Full Text] [Related]
8. Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics.
Inokuchi T; Takahashi S; Hiraoka S; Toyokawa T; Takagi S; Takemoto K; Miyaike J; Fujimoto T; Higashi R; Morito Y; Nawa T; Suzuki S; Nishimura M; Inoue M; Kato J; Okada H
J Gastroenterol Hepatol; 2019 Aug; 34(8):1329-1336. PubMed ID: 30724387
[TBL] [Abstract][Full Text] [Related]
9. Spacing the Administration Interval of Anti-TNF Agents: A Valid Strategy for Patients with Inflammatory Bowel Disease?
Torres P; Cañete F; Núñez L; Aguilar A; Mesonero F; Calafat M; Fernández C; Teniente A; Mañosa M; López-Sanromán A; Domènech E
Dig Dis Sci; 2020 Jul; 65(7):2036-2043. PubMed ID: 31858325
[TBL] [Abstract][Full Text] [Related]
10. New-onset Blepharitis and Anti-TNF-Alpha Therapy in Patients with Crohn's Disease: A Case Series and Literature Review.
Weintraub Y; Lev-Tzion R; Ollech J; Olshaker H; Rosen I; Cohen S; Varssano D; Shouval DS; Matar M
Isr Med Assoc J; 2023 Dec; 25(12):836-840. PubMed ID: 38142326
[No Abstract] [Full Text] [Related]
11. Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab.
Mañosa M; Domènech E; Marín L; Olivé A; Zabana Y; Cabré E; Gassull MA
Gut; 2008 Apr; 57(4):559; author reply 559-60. PubMed ID: 18334664
[No Abstract] [Full Text] [Related]
12. Adalimumab-induced lupus erythematosus with central nervous system involvement in a patient with Crohn's disease.
Vannucchi V; Grazzini M; Pieralli F; Giannotta M; Biagioni C; Nozzoli C
J Gastrointestin Liver Dis; 2011 Jun; 20(2):201-3. PubMed ID: 21725519
[TBL] [Abstract][Full Text] [Related]
13. Pustular lesions in patients with Crohn disease and treatment with tumour necrosis factor-α inhibitors.
Balaguer-Franch I; Hernández de la Torre-Ruiz E; Lacasta-Plasin C; García-Piqueras P; Menchén-Viso L; Baniandrés-Rodríguez O
Clin Exp Dermatol; 2022 Feb; 47(2):453-455. PubMed ID: 34431537
[TBL] [Abstract][Full Text] [Related]
14. Experience With Anti-TNF-α Biologic Agents in Succession in Patients With Crohn's Disease: A Retrospective Analysis of a Single Center.
Ferges W; Rampertab SD; Shafqet M; Salimi Q; You G; Yousefzadeh E; Cheng JQ; Das KM
J Clin Gastroenterol; 2016 Apr; 50(4):326-30. PubMed ID: 25984976
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
[TBL] [Abstract][Full Text] [Related]
16. Risk of Infections with Anti-TNF Agents in Patients with Crohn's Disease After Elective Surgery.
Dai C; Huang YH
Dig Dis Sci; 2022 Apr; 67(4):1421-1422. PubMed ID: 33939139
[No Abstract] [Full Text] [Related]
17. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
[TBL] [Abstract][Full Text] [Related]
18. Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors.
Ward MG; Warner B; Unsworth N; Chuah SW; Brownclarke C; Shieh S; Parkes M; Sanderson JD; Arkir Z; Reynolds J; Gibson PR; Irving PM
Aliment Pharmacol Ther; 2017 Jul; 46(2):150-161. PubMed ID: 28481014
[TBL] [Abstract][Full Text] [Related]
19. Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients.
Lightner AL; McKenna NP; Alsughayer A; Loftus EV; Raffals LE; Faubion WA; Moir C
J Pediatr Surg; 2019 Oct; 54(10):2162-2165. PubMed ID: 30773391
[TBL] [Abstract][Full Text] [Related]
20. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
